This company listing is no longer active
NeuBase Therapeutics Past Earnings Performance
Past criteria checks 0/6
NeuBase Therapeutics has been growing earnings at an average annual rate of 26.6%, while the Biotechs industry saw earnings growing at 14.7% annually.
Key information
26.6%
Earnings growth rate
28.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -170.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?
Aug 26
NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04
Aug 11NeuBase Therapeutics promotes Dr. William Mann to President and COO
Jun 29We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully
May 12Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?
Jan 24Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation
Oct 02Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation
Jun 02Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?
Feb 23We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth
Jan 19NeuBase Therapeutics EPS in-line
Dec 23NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy
Dec 16Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?
Dec 15Revenue & Expenses Breakdown
How NeuBase Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -25 | 11 | 13 |
| 31 Dec 22 | 0 | -30 | 12 | 18 |
| 30 Sep 22 | 0 | -34 | 12 | 21 |
| 30 Jun 22 | 0 | -33 | 13 | 20 |
| 31 Mar 22 | 0 | -33 | 13 | 20 |
| 31 Dec 21 | 0 | -29 | 12 | 17 |
| 30 Sep 21 | 0 | -25 | 12 | 14 |
| 30 Jun 21 | 0 | -23 | 11 | 13 |
| 31 Mar 21 | 0 | -18 | 10 | 9 |
| 31 Dec 20 | 0 | -17 | 10 | 8 |
| 30 Sep 20 | 0 | -17 | 10 | 7 |
| 30 Jun 20 | 0 | -33 | 13 | 19 |
| 31 Mar 20 | 0 | -31 | 12 | 18 |
| 31 Dec 19 | 0 | -29 | 11 | 17 |
| 30 Sep 19 | 0 | -26 | 9 | 16 |
Quality Earnings: NBSE is currently unprofitable.
Growing Profit Margin: NBSE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NBSE's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NBSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NBSE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: NBSE has a negative Return on Equity (-170.17%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/13 14:20 |
| End of Day Share Price | 2024/05/13 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NeuBase Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Whitney Ijem | Guggenheim Securities, LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |